90 related articles for article (PubMed ID: 21078129)
1. Strong cytotoxic effect of the bradykinin antagonist BKM-570 in ovarian cancer cells--analysis of the molecular mechanisms of its antiproliferative action.
Jutras S; Bachvarova M; Keita M; Bascands JL; Mes-Masson AM; Stewart JM; Gera L; Bachvarov D
FEBS J; 2010 Dec; 277(24):5146-60. PubMed ID: 21078129
[TBL] [Abstract][Full Text] [Related]
2. Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists.
Stewart JM; Gera L; Chan DC; York EJ; Simkeviciene V; Bunn PA; Taraseviciene-Stewart L
Peptides; 2005 Aug; 26(8):1288-91. PubMed ID: 15878795
[TBL] [Abstract][Full Text] [Related]
3. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
4. Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-gamma expression.
Melichar B; Konopleva M; Hu W; Melicharova K; Andreeff M; Freedman RS
Gynecol Oncol; 2004 Apr; 93(1):149-54. PubMed ID: 15047229
[TBL] [Abstract][Full Text] [Related]
5. Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines.
Presneau N; Mes-Masson AM; Ge B; Provencher D; Hudson TJ; Tonin PN
Oncogene; 2003 Mar; 22(10):1568-79. PubMed ID: 12629520
[TBL] [Abstract][Full Text] [Related]
6. Ganoderma lucidum exerts anti-tumor effects on ovarian cancer cells and enhances their sensitivity to cisplatin.
Zhao S; Ye G; Fu G; Cheng JX; Yang BB; Peng C
Int J Oncol; 2011 May; 38(5):1319-27. PubMed ID: 21399867
[TBL] [Abstract][Full Text] [Related]
7. Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro.
Leong CT; Ong CK; Tay SK; Huynh H
Oncogene; 2007 Feb; 26(6):870-80. PubMed ID: 16862170
[TBL] [Abstract][Full Text] [Related]
8. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.
Macleod K; Mullen P; Sewell J; Rabiasz G; Lawrie S; Miller E; Smyth JF; Langdon SP
Cancer Res; 2005 Aug; 65(15):6789-800. PubMed ID: 16061661
[TBL] [Abstract][Full Text] [Related]
9. Microarray analysis of gene expression mirrors the biology of an ovarian cancer model.
Tonin PN; Hudson TJ; Rodier F; Bossolasco M; Lee PD; Novak J; Manderson EN; Provencher D; Mes-Masson AM
Oncogene; 2001 Oct; 20(45):6617-26. PubMed ID: 11641787
[TBL] [Abstract][Full Text] [Related]
10. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
11. [Study of bcl-2 antisense oligodeoxynucleotides on reversal of cisplatin resistance in ovarian cancer cell line A2780/DDP].
Li M; Yu LL; Cai LQ; Wang HB; Wang ZH; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):121-5. PubMed ID: 16640863
[TBL] [Abstract][Full Text] [Related]
12. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.
Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A
Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284
[TBL] [Abstract][Full Text] [Related]
13. The homeobox gene BARX2 can modulate cisplatin sensitivity in human epithelial ovarian cancer.
Sellar GC; Watt KP; Li L; Nelkin BD; Rabiasz GJ; Porteous DJ; Smyth JF; Gabra H
Int J Oncol; 2002 Nov; 21(5):929-33. PubMed ID: 12370737
[TBL] [Abstract][Full Text] [Related]
14. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.
Coukos G; Makrigiannakis A; Kang EH; Rubin SC; Albelda SM; Molnar-Kimber KL
Clin Cancer Res; 2000 Aug; 6(8):3342-53. PubMed ID: 10955822
[TBL] [Abstract][Full Text] [Related]
16. Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC).
Zietarska M; Maugard CM; Filali-Mouhim A; Alam-Fahmy M; Tonin PN; Provencher DM; Mes-Masson AM
Mol Carcinog; 2007 Oct; 46(10):872-85. PubMed ID: 17455221
[TBL] [Abstract][Full Text] [Related]
17. Microarray-analysis: a new approach to study the molecular mechanisms of thermo-chemotherapy.
Schulte JH; Schramm A; Pressel T; Klein-Hitpass L; Kremens B; Eils J; Havers W; Eggert A
Klin Padiatr; 2003; 215(6):298-302. PubMed ID: 14677092
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: therapeutic potential for ovarian cancer.
Zhang N; Wu ZM; McGowan E; Shi J; Hong ZB; Ding CW; Xia P; Di W
Cancer Sci; 2009 Dec; 100(12):2459-64. PubMed ID: 19769630
[TBL] [Abstract][Full Text] [Related]
19. Expression of CD40 and growth-inhibitory activity of CD40 ligand in ovarian cancer cell lines.
Melichar B; Patenia R; Gallardo S; Melicharová K; Hu W; Freedman RS
Gynecol Oncol; 2007 Mar; 104(3):707-13. PubMed ID: 17166566
[TBL] [Abstract][Full Text] [Related]
20. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
